TTMS Blog
TTMS experts about the IT world, the latest technologies and the solutions we implement.
Posts by: Robert Moczulski
NIS2 Cybersecurity in Pharma Requirements, Obligations,and Implementation in 2026
NIS2 cybersecurity in pharma is an operational resilience requirement, not a stand-alone IT project. A cyber incident can stop a filling line, isolate a laboratory, interrupt a cold chain, corrupt a clinical dataset or make a validated system unavailable. Each outcome can affect product quality, patient safety and continuity of supply. Directive (EU) 2022/2555, known as NIS2, creates a common EU baseline for cybersecurity risk management, management oversight and significant-incident reporting. The legal duty is implemented through national law. A company must therefore read the Directive together with the rules, thresholds, registration procedures and competent-authority guidance in every Member State where it falls within scope. This guide converts the legal baseline into actions and evidence for pharmaceutical manufacturers, biotechnology companies, medicinal-product R&D organisations, contract manufacturing organisations (CMOs), contract research organisations (CROs) and their critical suppliers. It also explains where NIS2 must be aligned with GxP, Computerized System Validation (CSV), Computer Software Assurance (CSA), GAMP 5 and existing quality-management processes. This article covers pharma-specific implementation. For the detailed evidence model, see the TTMS NIS2 compliance documentation and evidence checklist. 1. Why pharmaceutical operations are a priority cyber target under NIS2 NIS2 places the manufacture of basic pharmaceutical products and pharmaceutical preparations within the health sector in Annex I, alongside healthcare providers, EU reference laboratories and entities carrying out research and development of medicinal products. That classification reflects systemic impact: disruption can affect access to medicines and public-health response, not only one company’s balance sheet. The threat picture supports that treatment. ENISA reported that, among health-related incidents analysed for its 2024 threat landscape, 45% involved ransomware and 28% involved data breaches. A separate commercial dataset counted 4,198 ransomware cases exposed on dark-web leak sites across all sectors in the first half of 2025, 49% more than in the comparable 2024 dataset. The 4,198 figure is not pharma-specific, so it should not be presented as a count of attacks on pharmaceutical or biotechnology organisations. Pharma combines assets that create leverage for attackers: intellectual property, clinical and patient-related data, regulated production, scarce batches, time-sensitive logistics and a broad supplier network. The same identity platform, integration layer or remote-maintenance channel may connect corporate IT with ERP, MES, LIMS, ELN, EDC and operational technology (OT). An attacker does not need to compromise every system. Disrupting one shared dependency may be enough to stop release, testing or distribution. Treat the business impact as a chain. Map each critical product or service to facilities, processes, systems, data, utilities, people and third parties. Record the maximum tolerable outage and the quality consequences of data loss or delayed review. That service map becomes evidence for risk analysis, business continuity, recovery priorities and supply-chain decisions. 2. NIS2 in life sciences: scope, classification and legal status NIS2 expanded the EU cybersecurity baseline beyond the narrower NIS1 model. It applies, as a rule, to medium-sized and large entities of a type listed in Annex I or Annex II, subject to specific inclusions and exceptions. In life sciences, the legal analysis must start with what the entity actually does—not the brand description “pharma”, “biotech” or “healthcare”. Activities may include medicinal-product R&D, API or finished-product manufacture, device manufacture, clinical operations, distribution, marketing, digital services or combinations of them. A group can contain entities with different statuses. A CMO or CRO is not automatically in or out merely because of its label. The relevant activity, size, establishment, jurisdiction and any national designation must be documented. 2.1 From NIS1 to NIS2: what changed for health and pharma NIS2 widens sector coverage, standardises a minimum set of cybersecurity risk-management measures, sets a staged significant-incident reporting model and strengthens supervision and enforcement. It requires management bodies to approve risk-management measures, oversee implementation and receive training. It also requires Member States to maintain national cybersecurity strategies and incident-response structures. The result is a common baseline, not identical administration across the EU. Registration, thresholds, forms, competent authorities, language, audit expectations and sanctions are implemented nationally. In July 2026, the Commission referred Ireland, Spain, France and the Netherlands to the Court of Justice for failing to notify full transposition. Cross-border groups still need a jurisdiction register and local legal verification. Existing GMP and quality-management governance can provide a starting structure. Management review, change control, deviation management, CAPA, supplier qualification, training and periodic review already create owners and records. Extend those processes to cybersecurity; do not assume that GxP evidence automatically proves NIS2 compliance. 2.2 Essential or important entity? Classify before selecting controls Under Article 3, an Annex I entity that exceeds the ceiling for a medium-sized enterprise is generally an essential entity. Other medium-sized entities within Annex I or Annex II are generally important entities, unless a specific rule or national designation changes the result. Certain entity types are essential regardless of size. Micro and small enterprises are generally excluded, but Article 2 contains exceptions based on criticality and other factors. Pure distribution or marketing activity may fall outside the listed pharma categories when the entity performs no covered activity and is not designated on another basis. Conversely, an organisation conducting medicinal-product R&D can fall within Annex I even if it does not manufacture. Medical-device coverage also requires careful reading of the relevant Annex category; not every device business has the same classification. Create a signed scope memorandum for each legal entity. Include activities, NACE or equivalent classification, headcount and financial data, establishments, services, national rules, group dependencies and the reason for the conclusion. Record who approved it and when it must be reviewed. This memorandum is the first auditable artefact; a product brochure or a group-level assumption is not enough. 3. Four compliance pillars for pharmaceutical organisations Organise NIS2 around four connected pillars: risk management, significant-incident reporting, management accountability and supply-chain security. Each needs an owner, a procedure and operating evidence. 3.1 Article 21 risk management: ten minimum areas Article 21 requires appropriate and proportionate technical, operational and organisational measures based on an all-hazards approach. The ten minimum areas below should be mapped to services and risks, not treated as a generic tool-purchasing list. Article 21 area Pharma implementation focus Typical audit evidence 1. Risk analysis and information-system security policies Link product, patient and service impact to IT, OT and GxP systems Approved method, service map, risk register, treatment decisions 2. Incident handling Coordinate security, quality, privacy, legal, production and communications Incident plan, severity matrix, case records, after-action reports 3. Business continuity, backup, disaster recovery and crisis management Prioritise batch, laboratory, release and cold-chain dependencies BIA, RTO/RPO, recovery plans, restore tests, exercise reports 4. Supply-chain security Assess API, CMO, CRO, logistics, cloud and maintenance dependencies Supplier tiering, due diligence, contracts, monitoring, exit plans 5. Secure acquisition, development and maintenance, including vulnerability handling and disclosure Connect security changes to validated-state and change-control decisions Security requirements, threat models, vulnerability records, change packages 6. Assessment of control effectiveness Test design, coverage and operating results Control tests, metrics, internal audits, CAPA and closure evidence 7. Cyber hygiene and training Train by role, including engineers, laboratory staff and management Curricula, attendance, competence checks, phishing or exercise results 8. Cryptography and encryption Protect data and communications while managing keys and certificates Cryptography standard, key inventory, certificate monitoring, exceptions 9. HR security, access control and asset management Control joiners, movers, leavers, privileged access and system ownership Asset register, access reviews, PAM records, segregation-of-duties evidence 10. MFA or continuous authentication and secure communications Cover remote access, privileged actions and exposed services based on risk MFA coverage, exception register, secure-channel configuration and reviews Build requirements traceability between each NIS2 measure, the service risk, the control, the system owner and the evidence source. Existing GxP processes can carry part of the load. Vulnerability remediation can use change control; control testing can align with periodic review and CSA; security training can use the controlled learning system. The mapping must also expose gaps. A validated application with no tested recovery process remains a continuity risk. 3.2 Article 23 reporting: 24 hours, 72 hours and one month For a significant incident, Article 23 establishes staged reporting: an early warning without undue delay and within 24 hours after becoming aware; an incident notification without undue delay and within 72 hours; and a final report no later than one month after the incident notification. Intermediate or progress reports may also be required. If the incident is ongoing at the one-month point, a progress report replaces the final report and the final report follows within one month after handling ends. The clock starts from awareness, not from completion of a forensic investigation. Define who can declare awareness, who assesses significance, who contacts the national CSIRT or competent authority and who coordinates parallel duties under GDPR, sector rules, contracts and, where relevant, medical-device obligations. Preserve both the decision to report and a reasoned decision not to report. Real-time visibility across identity, network, endpoint, cloud, ERP, MES, LIMS, ELN, EDC and OT improves the chance of meeting the timetable. A central SIEM can support detection and chronology, but it does not make a legal significance assessment. Use a human-in-the-loop process with on-call authority, a current contact list, pre-approved templates and a decision log. In validated environments, deploy monitoring through approved change control. Passive OT monitoring, network telemetry and controlled log forwarding may reduce interference with production assets. Test the entire route in a tabletop exercise: alert, technical triage, quality impact, legal assessment, management escalation, authority submission and follow-up. 3.3 Article 20: management responsibility and board-level evidence Management bodies must approve the Article 21 measures, oversee implementation and can be held liable for infringements under national law. Members must follow training, and Member States must encourage regular training for employees. Evidence should show informed oversight, not a ceremonial annual presentation. Provide the board with decisions it can act on: top service risks, overdue high-risk treatments, control effectiveness, significant incidents, recovery-test failures, critical supplier exposure, material exceptions and required investment. Retain agendas, papers, minutes, approvals, challenge and follow-up. Record training content, attendance and an effectiveness check. The Directive also allows competent authorities, in specified circumstances concerning essential entities, to request temporary suspension of a certification or authorisation and a temporary prohibition on certain senior managers exercising managerial functions until deficiencies are remedied. This is a supervisory measure with conditions, not an automatic personal ban after every incident. Avoid overstating it as criminal liability. 3.4 Article 21(2)(d): API, CMO, CRO and logistics risk Map suppliers to the services and products they can affect. Include API and excipient suppliers, CMOs, CROs, testing laboratories, packaging, cold-chain logistics, cloud platforms, managed services, equipment vendors, remote maintenance and single-source technology dependencies. Tier suppliers using impact, access, substitutability, concentration and recovery time. Due diligence should test the evidence relevant to the service: control scope, incident history, privileged access, subcontractors, vulnerability handling, backup and recovery, secure development, geographic concentration and exit feasibility. A questionnaire is a declaration; a certificate has value only after its scope, exclusions and period are checked. Contracts should define minimum controls, incident-notification timing, cooperation, audit or assurance rights, vulnerability handling, subcontractor conditions, data return, continuity and exit. Contract language does not replace monitoring. Record reviews, adverse findings, risk acceptance, compensating controls, owners and expiry dates. 4. Pharma-specific cybersecurity challenges NIS2 does not solve by itself NIS2 states outcomes and minimum risk areas. It does not prescribe how to patch a validated MES, monitor a PLC in a clean manufacturing area or preserve ALCOA+ principles during a cyber response. These decisions require security, quality, engineering and regulatory roles to work from one risk record. 4.1 Secure validated systems without losing validated state A security patch or configuration change can affect the validated state of MES, LIMS, QMS, chromatography, environmental-monitoring or other GxP systems. Delaying every patch is unsafe; applying every patch without assessment is also unsafe. The control objective is a documented, risk-based decision. Connect vulnerability management to change control. Record asset and version, vulnerability severity, exploitability, patient or product impact, exposure, vendor support, proposed change, test scope, rollback, compensating controls and approval. Use GAMP 5 and CSV or CSA principles to scale assurance to the risk of the changed function. Re-test what can affect intended use, data integrity, electronic records, interfaces and critical calculations. Maintain validated state throughout the lifecycle. Periodic review should reconcile configuration, deviations, patches, access, backup, audit trails, incidents and supplier changes. Emergency changes need predefined authority and retrospective quality review. Evidence should make the sequence traceable from threat to decision, test, release and post-implementation monitoring. 4.2 Protect clinical-trial data, IP and patient-related information NIS2 covers entities carrying out R&D activities of medicinal products when the scope and size rules are met. Their risk model must protect availability, authenticity, integrity and confidentiality across protocol design, investigator sites, eCOA, EDC, safety systems, biostatistics, regulatory submissions and partner exchanges. Apply ALCOA+ data-integrity thinking: records should remain attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring and available. Cyber controls must protect the audit trail and the context required to interpret data. Detect bulk data exports, unusual privileged activity, manipulation and unauthorised interface changes. Test restoration of both data and metadata. Privacy belongs in a coordinated but distinct assessment. A single event can create a NIS2 significant-incident question and a GDPR personal-data-breach question with different tests, recipients and deadlines. Maintain one fact base and timeline, then run separate legal decision paths. 4.3 IT/OT convergence in manufacturing and clean areas OT assets often have long lifecycles, vendor constraints, deterministic communications and limited maintenance windows. Standard endpoint agents may be unsupported. A production pause can itself create quality and supply consequences. Treat OT as a distinct engineering risk domain connected to enterprise governance. Begin with passive discovery and verified ownership. Define zones and conduits, restrict remote access, separate safety and control functions from business networks, protect engineering workstations, monitor allowed communications and control removable media. Use compensating controls when patching is not feasible. Confirm that segmentation and fail-safe behaviour do not disrupt real-time control or environmental conditions. Every change should have cyber, automation and quality acceptance criteria. Test during approved windows, document rollback and retain configuration baselines. The evidence package should include current diagrams, firewall rules, remote-access reviews, alert handling, backup or configuration-restore tests and approved exceptions. 5. NIS2, GDPR, MDR and quality systems: one management model NIS2 protects the resilience and security of network and information systems. GDPR protects personal data and creates breach-notification duties. MDR and IVDR govern medical devices and include safety, quality and post-market obligations. GMP and GxP govern product quality and data integrity. One incident can activate several regimes, but the legal tests are not interchangeable. Build one management model with multiple compliance mappings. Use a common service catalogue, asset register, risk method, incident record, supplier register, training process, CAPA workflow and evidence index. Map each control to the applicable NIS2 article, national law, GDPR requirement, quality procedure and device obligation. This reduces duplicate evidence without collapsing distinct decisions. Create a regulatory decision matrix before an incident occurs. For each regime, record the trigger, decision owner, recipient, deadline, minimum content and rule for follow-up. Add contractual notifications and communications to investigators, insurers, partners and affected customers. During an incident, one coordination lead should maintain the verified facts, while qualified owners make the separate legal and quality decisions. This model reduces contradictory reporting without allowing the shortest deadline to erase the distinct tests applied by each regime. ISO/IEC 27001 can provide a useful information-security management structure; it does not by itself prove NIS2 scope, registration or national reporting compliance. ISO/IEC 42001 can support governance where AI is used in LIMS analytics, quality review or security operations, but AI controls still require validation, data-integrity assessment and human oversight appropriate to the use case. Design an integrated incident form with separate sections for service impact, product and patient impact, personal data, regulatory status, notification decisions and communications. The same verified timeline can support the CSIRT, data-protection authority, quality unit and management without creating contradictory versions. 6. Penalties and enforcement: the cost of non-compliance Article 34 requires Member States to provide maximum administrative fines for essential entities of at least EUR 10 million or at least 2% of worldwide annual turnover in the preceding financial year, whichever is higher. For important entities, the corresponding levels are at least EUR 7 million or 1.4%, whichever is higher. National law determines the applicable enforcement process and may set higher maximums or additional measures. Fines are only one exposure. A cyber incident can generate lost sales, scrapped batches, delayed trials, recovery costs, contractual claims, privacy consequences and loss of confidence. Merck reported that its 2017 network attack disrupted manufacturing, research and sales, reduced 2017 sales by approximately USD 260 million and generated USD 285 million of manufacturing and remediation expense net of stated insurance recoveries; residual backlog affected 2018 sales by approximately USD 150 million. Do not justify controls only by comparing programme cost with the statutory maximum. Prioritise by service impact, credible threat, control weakness and legal duty. The board should see both compliance exposure and the operational loss scenario for each critical product or service. 7. A 9-12 month NIS2 implementation roadmap for pharma A 9-12 month programme can organise remediation, but it is not a legal grace period. Organisations already subject to national implementing law must meet current duties while improving maturity. Sequence work around critical risk and approved change windows in validated environments. 7.1 Step 1: scope and gap analysis Confirm each legal entity’s status and jurisdiction. Inventory critical services and products, then map IT, OT, laboratory, clinical, data, facility, people and supplier dependencies. Assess the ten Article 21 areas and national obligations. The assessment should produce an approved scope memorandum, jurisdiction register, service and dependency map, asset baseline, gap report, risk-ranked remediation plan and evidence index. Escalate any unknown externally exposed asset or unsupported critical system immediately. 7.2 Step 2: governance and accountability Assign executive sponsorship, service owners, control owners and an incident-reporting authority. Define RACI across security, IT, OT, engineering, quality, privacy, legal, procurement, HR, communications and business continuity. At this stage, the organisation should have a governance charter, RACI, management reporting pack, risk-acceptance thresholds, training plan, CSIRT contact matrix and defined authority for isolating production or laboratory systems. 7.3 Step 3: technical and organisational controls Prioritise identity, privileged access, MFA, network segmentation, secure remote access, EDR where supported, passive OT monitoring, central logging, vulnerability management, protected backups and recovery. Connect each change to quality and validation procedures. Completion is evidenced by approved architectures, control requirements, implementation records, validation or assurance evidence, coverage metrics, an exception register and tested rollback. Measure the population covered, not only whether a tool was purchased. 7.4 Step 4: supplier verification and continuous monitoring Tier API, CMO, CRO, laboratory, logistics, cloud, software and maintenance suppliers. Run due diligence proportional to access and impact. Remediate contracts and establish monitoring triggers. The operational output is a maintained supplier register supported by a criticality model, evidence reviews, risk decisions, security clauses, incident contacts, a monitoring schedule, concentration analysis and exit plans. Reassess after a material change or incident. 7.5 Step 5: build and test incident response Create playbooks for ransomware, data exfiltration, validated-system compromise, OT disruption, supplier incident and loss of a critical cloud service. Include quality and regulatory decisions, not only technical containment. The response capability should be documented in an incident plan, 24/72-hour and final-report templates, a significance assessment, an evidence-preservation method and a tabletop report. Run the exercise with executives and on-call personnel. Track corrective actions to verified closure. 7.6 Step 6: document, audit and sustain Convert control operation into evidence by design. Automate controlled reports where practical, identify record owners and set retention based on national law, sector duties, investigation needs and risk. Review the programme after incidents, major changes and legal updates. The programme closes with a controlled policy set, evidence index, management minutes, training records, incident and supplier files, recovery-test results, effectiveness testing, an internal-audit report and a CAPA register. Independent review should confirm closure of high-risk findings. 8. Documented cyber incidents: practical NIS2 lessons Public incident reports rarely prove which internal control failed. Use them to test plausible scenarios, not to accuse an organisation of a control deficiency that has not been established. Merck’s 2017 attack demonstrates that enterprise malware can reach manufacturing, research, sales and fulfilment at the same time. The NIS2 lesson is to map shared dependencies, segment environments, protect recovery capabilities and quantify product-level continuity. Exercise the decision to isolate a plant system when isolation may interrupt production. The 2020 cyberattack on the European Medicines Agency unlawfully accessed documents related to COVID-19 medicines and vaccines. EMA reported that some leaked material, including correspondence, had been manipulated before publication. The lesson is broader than confidentiality: protect authenticity, integrity and provenance across regulator and partner exchanges, and prepare communications for manipulated or incomplete data. Cencora disclosed in February 2024 that data had been exfiltrated from its information systems and might contain personal information. It stated at the time that operations remained functional and that containment, investigation, law-enforcement engagement and external support had begun. The lesson is to maintain rapid cross-functional triage even when availability is not affected: exfiltration can still trigger NIS2, privacy, contractual and trust decisions. For each scenario, retain the alert timeline, affected services, evidence sources, quality assessment, reporting decision, management escalation and corrective actions. Link lessons to Article 21 controls and test whether the same evidence could support the 24-hour early warning. 9. Selecting expert support for NIS2 implementation A pharma NIS2 partner must combine cybersecurity, regulated quality and implementation capability. Ask for evidence that the team can classify scope, map services, design IT/OT controls, manage validated change, build CSV or CSA evidence, assess suppliers, run incident exercises and explain residual risk to management. Evaluate the delivery model. A one-time gap report does not sustain compliance. Managed services can operate monitoring, vulnerability triage, evidence collection and supplier review, but accountability remains with the regulated organisation and its management. Define ownership, escalation, service levels, evidence access and exit from the start. Request sample deliverables before selection: a redacted scope memorandum, an Article 21 traceability matrix, a validated change package, an OT risk assessment, a supplier finding and an executive incident exercise report. Check whether conclusions identify assumptions, evidence and residual risk. Confirm that security specialists can work with quality, automation and legal teams, and that records can be transferred into the organisation’s controlled repositories. The partner should leave the organisation with an operating process and usable evidence, not a slide deck that cannot be maintained. TTMS combines an ISO/IEC 27001 information-security management environment with pharmaceutical computerized-system validation services aligned to GAMP 5 and Annex 11. Its published quality offering covers CSV and CSA across the system lifecycle. In February 2026, TTMS reported becoming the first Polish company to obtain accredited ISO/IEC 42001 certification for its AI management system after an audit by TÜV Nord Poland. These credentials are relevant where cyber controls, validated systems and governed AI must remain auditable in one operating model. To arrange a scoping call focused on legal entities, regulated services, critical products, validated systems, OT dependencies and current evidence, contact TTMS. The first output should be a defensible scope and prioritised action plan—not a generic control catalogue. 10. Frequently asked questions about NIS2 cybersecurity in pharma Does NIS2 apply to every pharmaceutical company? No. Scope depends on activity, size, establishment, national law and designation. Manufacturing and medicinal-product R&D are listed; marketing or distribution alone may lead to a different result. Document the conclusion for each legal entity. Is every pharmaceutical manufacturer an essential entity? No. Annex I classification does not automatically make every manufacturer essential. Size thresholds, Article 3 rules, exceptions and national decisions determine whether an organisation is essential, important or outside scope. Group companies may reach different conclusions. What are the main NIS2 incident-reporting deadlines? For a significant incident, the Directive sets an early warning within 24 hours of awareness, an incident notification within 72 hours and a final report within one month. National procedures and parallel duties under GDPR or sector rules must also be checked. How do NIS2, GxP and Annex 11 interact in pharmaceutical environments? NIS2 governs cyber risk and resilience; GxP and Annex 11 govern product quality, data integrity and computerized systems. Use one risk and change-control model while preserving separate legal assessments and validation evidence for security changes. How should security patches be handled in validated GxP systems? Route the vulnerability through risk assessment and controlled change. Document exploitability, product or patient impact, test scope, rollback and compensating controls. Apply CSV or CSA assurance proportionate to the affected function and retain traceability from the vulnerability to approval and post-change review.
Read
NIS2 Compliance Documentation: What Evidence Should Businesses Prepare?
NIS2 compliance cannot be demonstrated by a policy library alone. A regulator, auditor or management body may need to understand not only what an organisation intended to do, but also whether its cybersecurity measures were approved, implemented, tested and improved over time. That distinction makes evidence management a central part of NIS2 readiness. Policies describe the expected approach. Evidence shows that people followed it, controls operated, exceptions were governed and material weaknesses reached the right decision-makers. Directive (EU) 2022/2555, known as NIS2, does not prescribe one universal folder of documents for every regulated entity. It establishes outcomes and minimum areas that essential and important entities must address through appropriate and proportionate technical, operational and organisational measures. The exact records expected from an entity depend on its risk profile, services, sector, size, national implementing law and, in some cases, sector-specific EU rules. This guide explains how businesses can build practical NIS2 compliance documentation, what evidence may support Articles 20, 21 and 23 of the Directive, and how to organise a defensible evidence pack without creating unnecessary bureaucracy. It is designed as a documentation and assurance guide—not as another general implementation roadmap or audit checklist. 1. Does NIS2 require specific compliance documentation? NIS2 does not contain a single exhaustive schedule titled “documents every entity must maintain”. Instead, it creates duties that are difficult to perform or demonstrate without reliable records. Article 20 requires management bodies of essential and important entities to approve cybersecurity risk-management measures, oversee their implementation and follow relevant training. Article 21 requires appropriate and proportionate risk-management measures covering at least ten specified areas. Article 23 establishes staged reporting for significant incidents. Supervision provisions allow competent authorities to request information and access data, documents or other evidence needed for their tasks. As a result, documentation should support three questions: What decision, process or control was required? Who approved, owned or performed it, and when? What evidence shows that it operated and produced the intended result? National legislation may define additional documents, registration information, audit requirements, reporting forms or retention periods. Organisations operating in several Member States should therefore maintain a jurisdiction register instead of assuming that one evidence pack satisfies every national procedure. Certain DNS, cloud, data-centre, managed service, managed security, online marketplace, online search, social networking and trust service providers are also subject to Commission Implementing Regulation (EU) 2024/2690. For those entities, the Regulation and ENISA’s supporting technical guidance provide more detailed requirements and examples. Other entities may use that material as a reference, but should not present it as automatically binding outside its legal scope. 2. Documentation, records and evidence: what is the difference? These terms are often used interchangeably, but separating them improves assurance. Category Purpose Examples Governing documents Define what the organisation expects and who is responsible Policies, standards, procedures, governance charters and control descriptions Operational records Show that a process or control was performed Access reviews, vulnerability tickets, backup logs, supplier assessments and training records Decision evidence Shows how risks, exceptions and priorities were considered Management minutes, risk acceptance, investment approvals and escalation records Effectiveness evidence Shows whether measures work as intended Test results, restoration exercises, metrics, audits and verified remediation Regulatory records Support registration, notification and supervisory engagement Scope analysis, authority correspondence, incident reports and information requests A policy is not proof that the process operates. A screenshot is not necessarily reliable evidence if its source, date, scope and owner are unclear. A test report has limited value if no one owns the findings or verifies their closure. Strong evidence connects design with operation. It should allow a reviewer to trace a requirement to a control, the control to its owner, the owner to operational records and any failure to a documented decision or corrective action. 3. Build a NIS2 evidence map before collecting files Collecting everything creates cost, confusion and additional security risk. A better approach begins with an evidence map. An evidence map links each applicable obligation to the entity’s controls and records. It can be maintained in a governance, risk and compliance platform or a controlled spreadsheet, provided ownership, versioning and access are appropriate. Evidence-map field What to record Legal or control reference Applicable NIS2 article, national provision, implementing rule or internal control requirement Expected outcome The risk or service outcome the measure should achieve Control description How the organisation addresses the outcome Owner and operator Who is accountable and who performs the activity Evidence source System, repository or process producing the record Frequency or trigger Monthly, quarterly, annually, after change or after an incident Reviewer Who assesses completeness and effectiveness Retention and protection How long evidence is kept and how access and integrity are protected Status and exceptions Current result, open gaps, accepted risk and remediation The map should reflect the services and systems in scope. A generic template can accelerate the work, but it should not become the basis for unsupported declarations. Where a control does not apply, the organisation should record the reason rather than leaving an unexplained blank. 4. Scope and applicability records An organisation cannot build credible NIS2 compliance documentation without first establishing which entities and services are covered. Scope evidence is especially important for corporate groups, cross-border operations and businesses whose activities cross several sectors. A documented applicability file may include: a list of relevant legal entities and establishments; services and activities mapped to Annex I or Annex II of NIS2 and corresponding national provisions; employee and financial data used for size classification; analysis of partner and linked enterprises where relevant to SME calculations; size-independent rules and any specific designation decisions; jurisdiction and competent-authority mapping; interaction with sector-specific EU legislation, such as DORA; legal advice or internal interpretation supporting uncertain classifications; review triggers for acquisitions, new services, restructuring and legislative change. The purpose is not to produce a long legal memorandum for every entity. It is to make the conclusion reproducible. A reviewer should be able to see what facts were considered, which version of the law was used and who approved the result. Scope documentation should also identify the network and information systems supporting covered services. Legal entity boundaries do not always match technical boundaries. Shared identity platforms, cloud tenants, data centres or managed providers may support several companies and services, making dependency evidence important. 5. Governance and management-body evidence Article 20 makes management involvement a substantive requirement. Evidence should show more than the presence of cybersecurity on an annual agenda. 5.1 Approval of cybersecurity risk-management measures Approval evidence can include board or management-body minutes, resolutions, decision papers and approved policy sets. The record should identify what was approved, the scope of the decision, material risks, known limitations, required resources and the reporting mechanism used to oversee implementation. Where a large package is approved, a controlled index can identify all included documents and their versions. This avoids uncertainty about whether a policy was actually part of the decision. 5.2 Oversight of implementation Oversight records may include periodic dashboards, risk committee minutes, programme status reports, overdue-action escalations and decisions concerning residual risk. Reporting should enable informed challenge. Useful indicators connect controls with service outcomes. Examples include the proportion of critical services covered by tested recovery plans, overdue remediation for critical vulnerabilities, privileged access awaiting review, critical suppliers without current assurance and high-risk audit findings past their agreed date. Raw activity counts are weaker. The number of alerts processed or employees trained may be relevant, but it does not by itself show whether the organisation can protect and recover its services. 5.3 Management training Training evidence should record the audience, date, subject matter, facilitator and completion. The content should help management understand its responsibilities, the entity’s threat and risk profile, significant-incident escalation, risk acceptance and oversight expectations. An attendance list alone may not demonstrate that training was suitable. Agenda materials, learning objectives, exercises or confirmation of understanding provide stronger context. 5.4 Accountability and delegated responsibility An organisation should maintain a current responsibility model. This can include governance terms of reference, role descriptions, RACI matrices, escalation paths and authority for risk acceptance. Operational tasks may be delegated to security teams, technology owners or providers. Documentation should still show how the management body receives assurance and how material matters are escalated. Outsourcing a control does not outsource the regulated entity’s responsibility for managing its risk. 6. Risk-analysis and treatment evidence Article 21 begins with policies on risk analysis and information-system security. A defensible evidence trail demonstrates that risk management affects decisions and investment. Core documentation may include: the approved cybersecurity risk methodology; risk criteria, impact scales and likelihood definitions; a service, process, information and technology inventory; risk assessments and a current risk register; treatment plans with owners, resources and deadlines; risk acceptance and exception records; reassessment after material change or an incident; links between risks, controls, suppliers and continuity priorities. The risk register should not be an isolated spreadsheet owned only by the security team. Material risks need accountable business owners and a route to management. Treatment records should make clear whether the organisation is reducing, avoiding, transferring or accepting the risk. Exceptions require particular care. A patching exception, unsupported system or delayed access review should identify the affected service, reason, compensating measures, approver, expiry date and review. Open-ended exceptions weaken both security and evidence quality. 7. Evidence for the Article 21 risk-management areas The following examples illustrate records that may support the ten minimum areas in Article 21. They are not a universal statutory checklist. Article 21 area Examples of useful evidence Risk analysis and system-security policies Methodology, risk register, policy approvals, review history and exception records Incident handling Response plan, severity criteria, incident tickets, communication logs, exercise reports and lessons learned Business continuity, backup and crisis management Business impact analysis, recovery objectives, continuity plans, backup monitoring, restoration results and crisis exercises Supply-chain security Supplier inventory, risk tiering, due diligence, security clauses, assurance reports, monitoring and exit plans Secure acquisition, development and maintenance Security requirements, architecture reviews, secure-development records, change approvals, vulnerability tickets and patch evidence Assessment of effectiveness Control testing, penetration tests, audits, metrics, findings and verified remediation Cyber hygiene and training Baseline standards, update and configuration records, role-based training, simulations and follow-up actions Cryptography and encryption Cryptographic policy, approved standards, key and certificate inventories, rotation logs and exception decisions Human resources security, access and assets Screening where lawful, joiner-mover-leaver records, access reviews, privileged-account evidence and asset inventories MFA and secure communications Coverage reports, enrolment and recovery controls, exception records, authentication tests and emergency communication exercises Evidence must remain proportionate. A small important entity and a multinational essential entity may address the same legal area with different operating models and documentation depth. The key question is whether the record is sufficient to demonstrate the control in the context of the entity’s risk. 8. Incident-reporting documentation Article 23 requires essential and important entities to notify significant incidents through a staged process. The Directive provides for an early warning without undue delay and within 24 hours of awareness, an incident notification within 72 hours, and generally a final report within one month of the incident notification. Intermediate or progress reports may also be required. Incident evidence should support both response and the reporting decision. Useful records include: the time and source of initial detection; the point at which the organisation became aware of the incident; technical and business severity assessments; the significant-incident assessment and its approver; affected services, systems, users and other persons; suspected malicious or unlawful activity; indicators of compromise and cross-border implications where available; containment, mitigation and recovery actions; copies of regulatory submissions and acknowledgements; customer, contractual, data-protection and law-enforcement communications; decision logs showing what was known and unknown at each stage; root-cause findings, lessons learned and corrective actions. 8.1 Preserve a reporting timeline The reporting clock can begin before a complete forensic conclusion is available. A reliable timeline is therefore essential. Systems should use synchronised time sources, and the incident lead should record material decisions as they occur. The evidence should distinguish facts, assumptions and pending investigation. Early notifications can be qualified. A clear record of uncertainty is more credible than retrospective notes that imply the organisation knew everything at the start. 8.2 Document non-reporting decisions Not every security event meets the threshold of a significant incident. When an event is assessed as non-reportable, the organisation should retain a proportionate record of the facts, criteria and decision. This helps demonstrate consistency and enables later reassessment if the impact changes. National law, authority guidance and the Commission Implementing Regulation for specified digital and ICT entities may provide additional thresholds and procedural detail. Reporting templates and contact information should be maintained for every relevant jurisdiction. 9. Supply-chain and supplier evidence Supplier documentation should show that the organisation understands which relationships could affect its covered services and applies scrutiny proportionate to the risk. An evidence set may contain: a supplier inventory linked to services and information assets; inherent-risk and criticality classifications; due-diligence questionnaires and supporting documents; independent assurance reports and certifications, with scope and exceptions reviewed; security requirements in contracts and statements of work; incident-notification and cooperation provisions; subcontracting, location and concentration-risk information; access granted to supplier personnel and periodic access reviews; performance, vulnerability and incident monitoring; reassessment records following change or an incident; continuity, substitution and secure-exit plans. A certificate should not be stored without analysis. Its scope, period, exclusions and relationship to the delivered service matter. Similarly, a completed questionnaire is a supplier statement, not independent proof. Higher-risk suppliers may require interviews, technical evidence, independent reports or contractual verification rights. Documentation should also record the organisation’s response to deficiencies. Accepting a supplier risk without an owner, expiry date or compensating measure creates an unmanaged exception. 10. Business continuity, backup and recovery evidence Continuity documentation should connect business priorities with technical recovery capability. The evidence chain may begin with business impact analysis and service dependency maps. These should support recovery time and recovery point objectives, response priorities, backup architecture, alternative procedures and supplier arrangements. Operational evidence can include: current continuity, disaster-recovery and crisis-management plans; protected backup configuration and monitoring; restoration tests showing which data and systems were recovered; actual recovery duration compared with approved objectives; test limitations, failures and remediation; exercise attendance, decisions and lessons learned; emergency contacts and out-of-hours escalation checks; evidence that critical providers participated where relevant. A successful backup job is not the same as a successful recovery. Evidence should demonstrate that required data can be restored into an operable service under plausible conditions. Testing should vary scenarios. Tabletop exercises are useful for decisions and communication, while technical restoration tests provide evidence of recovery capability. More complex entities may use integrated exercises involving suppliers, facilities and business teams. 11. Security-control and technical evidence Technical evidence is often abundant but difficult to interpret. The objective is not to export every log. It is to retain records that demonstrate scope, operation, review and response. Examples include: approved secure-configuration baselines and compliance reports; vulnerability scan coverage and remediation tickets; patch status linked to criticality and exceptions; endpoint, network and cloud monitoring coverage; identity and privileged-access reviews; MFA coverage and bypass exceptions; encryption, key and certificate management records; change approvals and security testing; secure-development and dependency-scanning results; asset inventory completeness checks; alert investigations and response outcomes. Tool screenshots should be used carefully. Prefer repeatable reports or system exports with the source, timestamp, query scope and responsible reviewer recorded. Evidence should be protected from unauthorised modification, particularly when it may support an investigation. 12. Evidence that measures are effective Article 21 includes policies and procedures to assess the effectiveness of cybersecurity risk-management measures. This means documentation should go beyond implementation status. An effectiveness file can combine: defined control objectives and success criteria; control self-assessments; technical testing and independent review; security and resilience metrics; internal and external audit reports; incidents and near misses indicating control performance; trends and recurring weaknesses; corrective actions with owners and deadlines; proof that high-risk remediation was independently verified. Metrics should be interpreted. For example, “98% of critical systems patched on time” requires a defined population, a reliable inventory, treatment of exceptions and information about the remaining 2%. A positive average can conceal exposure in a critical service. Management reporting should distinguish control design, implementation and effectiveness. A control can be well designed but inconsistently operated, or widely deployed but ineffective against a realistic threat. 13. How to assemble a NIS2 evidence pack An evidence pack is a controlled view of relevant records, not a permanent duplicate of every operational file. 1. Start with an index The index should identify the requirement, document or evidence item, owner, version or period, source location, access classification and review status. It should also identify unavailable evidence and open remediation. 2. Use service-based navigation Regulatory obligations apply to entities, but operational impact occurs through services. Organising evidence around covered services helps reviewers understand dependencies, risks, controls and recovery priorities. 3. Select representative periods and samples Evidence should show operation over time. One access review performed immediately before an assessment does not demonstrate a mature quarterly process. Samples should cover the relevant period, locations and technologies. 4. Preserve source and context Each item should make clear where it came from, who produced or approved it, the date, scope and meaning. Remove unexplained screenshots, unlabeled exports and drafts that could be mistaken for approved records. 5. Record gaps honestly Do not create evidence retrospectively to imply that an activity occurred. Where evidence is missing, document the gap, immediate risk response, owner and remediation date. Transparent remediation is more defensible than an unreliable record. 6. Perform quality review Legal, security, risk and service owners should check consistency. The asset inventory should agree with vulnerability coverage. Supplier classification should drive assurance. Recovery objectives should match test reports. Management minutes should reflect the material risks shown in dashboards. 14. Evidence quality principles A practical evidence standard can be expressed through seven characteristics: relevant: it supports a defined requirement or control; authentic: its origin and ownership can be established; complete: it includes the scope and context needed for interpretation; accurate: it reflects what actually occurred; timely: it covers the required period and was produced at the appropriate time; protected: access, integrity and confidentiality are controlled; retrievable: authorised teams can find it when required. These principles help teams decide whether a proposed record adds assurance or merely volume. 15. Retention, confidentiality and evidence security NIS2 does not establish one universal retention period for every type of compliance record. Retention should be determined using national requirements, limitation periods, sector rules, contractual duties, audit cycles, incident-investigation needs and the organisation’s risk. Evidence may contain sensitive architectural details, vulnerabilities, personal data, credentials, supplier information or legal advice. It should be classified and protected accordingly. Collecting material for an assessment does not justify placing unrestricted copies in a shared folder. The organisation should define: approved repositories and access roles; version control and approval status; retention and defensible disposal; legal hold and investigation procedures; integrity protection and backup; secure transfer to auditors or authorities; handling of personal and privileged information; return or deletion of assessment copies. Data minimisation matters. Evidence should be sufficient for its purpose without exposing unnecessary personal data, secrets or complete security configurations. 16. Common NIS2 documentation mistakes 16.1 Treating policies as proof of operation Policies establish intent. They need corresponding reviews, logs, tests, decisions and corrective actions. 16.2 Collecting screenshots without context A screenshot may not show the source, date, population, filters or reviewer. Use controlled exports and explanatory notes where possible. 16.3 Building the evidence pack only before an audit Last-minute collection produces gaps and inconsistent records. Evidence generation should be embedded into normal control operation. 16.4 Keeping expired exceptions open Exceptions should have owners, compensating measures and expiry dates. Repeated extensions require appropriate challenge and escalation. 16.5 Storing sensitive evidence too broadly Centralisation improves retrieval but can create a valuable target. Use classification, least privilege, logging and secure transfer. 16.7 Ignoring contradictory records An approved policy may claim quarterly reviews while operational records show annual activity. Resolve discrepancies instead of presenting them as separate truths. 16.8 Equating certification with complete NIS2 evidence ISO/IEC 27001 certification can provide useful governance and control records. It does not automatically demonstrate legal scope, national notification procedures or every NIS2 outcome. The certification scope and statement of applicability must be understood. 17. NIS2 compliance documentation checklist Use this checklist as a planning aid. Adapt it to the entity, national law and risk profile. [ ] Applicability and jurisdiction analysis is documented and approved. [ ] Covered services, systems, data, people, facilities and suppliers are mapped. [ ] Management approval of risk-management measures is traceable. [ ] Management oversight and cybersecurity training records are current. [ ] Roles, escalation paths and risk-acceptance authority are defined. [ ] Risk methodology, assessments, register and treatment plans are maintained. [ ] Policies are version-controlled, approved and linked to operating procedures. [ ] Incident records preserve awareness, decisions, actions and reporting timelines. [ ] Non-reporting decisions for material events use documented criteria. [ ] Continuity and recovery documentation is linked to critical services. [ ] Backup and restoration evidence demonstrates recoverability. [ ] Supplier inventory, classification, due diligence and monitoring are current. [ ] Security clauses and supplier-exit arrangements reflect criticality. [ ] Vulnerability, patch, configuration and change records show control operation. [ ] Access, privileged accounts and MFA exceptions are reviewed. [ ] Cryptographic keys and certificates are governed and monitored. [ ] Training evidence is role-based and includes effectiveness indicators. [ ] Control testing and audits produce owned, time-bound remediation. [ ] High-risk findings have verified evidence of closure. [ ] Evidence retention, access, integrity and secure transfer are defined. [ ] The evidence index identifies missing or outdated records. [ ] Evidence is reviewed after major incidents, changes and regulatory updates. 18. How this guide fits with implementation and audit work Documentation should emerge from real controls. Organisations that are still designing their programme can use TTMS’s practical guide to implementing NIS2 for a broader implementation perspective. For a general overview of business duties, see cybersecurity obligations of businesses under NIS2. An implementation programme creates and operates controls. An evidence programme makes their ownership, decisions and results demonstrable. An audit or assessment then evaluates whether the measures and evidence satisfy the applicable criteria. These activities support one another but should not be confused. 19. Why TTMS? Building a NIS2 evidence model requires an understanding of regulation, governance and the technology that generates operational records. TTMS can support organisations in mapping applicable requirements to services, controls, owners and evidence sources, then integrating those records into practical workflows. Support may include evidence-readiness assessments, governance and responsibility design, control mapping, documentation frameworks, supplier assurance, incident and continuity exercises, technical-control verification and remediation planning. The objective is not to create documents for their own sake. It is to help the organisation establish records that reflect working security measures and provide management with reliable assurance. Engagement scope should be tailored to the entity’s legal position, national requirements, risk profile and existing management systems. Legal conclusions should be confirmed by appropriately qualified advisers, while technical and organisational evidence should support those conclusions accurately. 20. Prepare a defensible NIS2 evidence pack Organisations should not wait for an authority request or audit notice before locating their records. Start with the services in scope, the decisions management must make and the controls protecting those services. Then identify which reliable records demonstrate operation and effectiveness. Contact TTMS to discuss a NIS2 documentation and evidence-readiness assessment tailored to your organisation. For authoritative background, consult the European Commission overview of the NIS2 Directive, ENISA’s NIS2 implementation resources and the official text of Directive (EU) 2022/2555 on EUR-Lex. 21. Frequently asked questions about NIS2 compliance documentation What documentation is required for NIS2 compliance? NIS2 does not prescribe one universal document pack. Covered entities need records sufficient to demonstrate management approval and oversight, appropriate and proportionate risk-management measures, significant-incident reporting and compliance with applicable national procedures. Typical evidence includes scope analysis, governance decisions, risk records, policies, operational control records, supplier assurance, continuity tests, incident files, metrics, audits and remediation. Is a policy enough to prove NIS2 compliance? No. A policy describes the intended approach. Evidence of operation may include approvals, system records, reviews, test results, incidents, exceptions and corrective actions. A reviewer should be able to connect the policy to actual controls and accountable owners. Does NIS2 require an information security management system? NIS2 requires a governed set of appropriate and proportionate cybersecurity risk-management measures. National law may expressly require an information security management system, and an ISMS is a practical way to organise policies, risk management, controls and improvement. Organisations should verify the terminology and detailed requirement in each relevant jurisdiction. Does ISO 27001 certification provide sufficient evidence? ISO/IEC 27001 certification can provide valuable evidence, but it is not automatic proof of complete NIS2 compliance. The certification scope, exclusions and statement of applicability matter. Legal scope, management duties, national registration and incident-reporting procedures still require specific assessment. How long should NIS2 evidence be retained? There is no single NIS2 retention period covering every record. The organisation should define retention using national law, sector obligations, audit cycles, limitation periods, contractual duties, investigation needs and risk. Sensitive evidence should be disposed of securely when retention is no longer justified. Should every security log be placed in the evidence pack? No. The pack should provide a controlled view of relevant evidence. Operational logs may remain in their source systems, with an index describing ownership, scope, retention and retrieval. Export only what is necessary and protect sensitive technical information. What evidence should the management body receive? Management should receive information enabling approval and effective oversight: material risks, measure implementation, significant incidents, control failures, critical supplier exposure, effectiveness results, overdue high-risk actions and decisions requiring acceptance or investment. How should incident-reporting decisions be documented? Record awareness time, affected services, severity and impact, applicable thresholds, known and unknown facts, the decision-maker and the basis for reporting or not reporting. Keep copies of notifications, acknowledgements and subsequent updates. Follow applicable national procedures. What supplier evidence is useful for NIS2? Useful records include supplier criticality, due diligence, assurance reports, contractual security provisions, access reviews, monitoring, incident cooperation, continuity arrangements and exit plans. Evidence depth should reflect the supplier’s access and potential impact on covered services. How often should the NIS2 evidence pack be reviewed? Set a risk-based schedule and update records through normal operations. Additional review should follow material incidents, acquisitions, major system or service changes, new critical suppliers, significant control failures and legal updates. Who should own NIS2 compliance documentation? Ownership is distributed. Legal or compliance teams may maintain the requirements map, while security, IT, service owners, procurement, HR and continuity teams own operational records. A central coordinator should manage the evidence index, quality checks and escalation without becoming the artificial owner of every control.
Read
5 Most Common Gaps Identified When Preparing for KSC 2.0
Preparing an organization for KSC 2.0 involves more than drafting security policies and incident response procedures. Only an assessment of how the organization actually operates can show whether documented rules are followed in practice, responsibilities have been clearly assigned and teams can respond effectively under time pressure. It is particularly important now that the Polish amendment to the Act on the National Cybersecurity System, implementing the NIS2 Directive, is already in force. The provisions took effect on 3 April 2026. Entities that met the criteria for classification as a key or important entity on that date and are not entered ex officio in the KSC Register should submit an application for entry by 3 October 2026. Organizations are therefore no longer preparing for a future regulation; they are implementing specific obligations concerning, among other things, risk management, incident handling, business continuity and supplier security. Based on gap analyses and compliance audits conducted by TTMS experts in 2026, we have observed that the issue is rarely a single isolated non-compliance. More often, organizations face several interconnected deficiencies that can make it harder to meet statutory requirements and delay incident response. This article presents the five gaps we identify most frequently, their practical consequences and the areas that should be verified first. 1. What Is a NIS2 Audit and Why Does Your Organization Need One? A NIS2 audit is an assessment process used to determine how effectively an organization meets the requirements of the Directive and the Polish Act on the National Cybersecurity System. In practice, TTMS auditors review IT systems, risk management procedures and incident response plans, and then compare the actual state of operations with the applicable legal obligations. The assessment of security measures is based primarily on Article 21 of the NIS2 Directive and Article 8 of the KSC Act, which requires the implementation of an information security management system. Organizations that verify compliance early gain time to implement improvements in a controlled manner instead of acting under the pressure of an inspection. 1.1 The NIS2 Directive in Brief The NIS2 Directive is an EU legislative act on the security of network and information systems that replaced the earlier NIS framework. It introduces significantly stricter requirements than its predecessor, particularly for organizations whose operations are important to the functioning of the state and the economy. Its purpose is to harmonize security standards across the European Union and materially strengthen resilience against cyberattacks. 1.2 Purpose and Scope of a NIS2 Compliance Audit The purpose of an audit is to assess the extent to which an organization meets the Directive’s requirements and to identify specific security gaps together with a remediation plan. The scope covers both technical matters, such as network configuration and access management, and organizational matters, including security policies, risk management procedures and business continuity plans. A well-executed audit produces an actionable implementation roadmap, not merely a list of deficiencies. 2. Who Is Subject to KSC 2.0 and When Is an Audit Required? The amendment covers key and important entities operating in the sectors listed in Annexes 1 and 2 to the Act, including energy, transport, healthcare, digital infrastructure, selected manufacturing industries and digital services. Whether an organization falls within the scope of the Act depends on its sector, type of activity, company size and specific statutory criteria. Some entities are covered regardless of their headcount or turnover. 2.1 Covered Sectors and Company Size The threshold of 50 employees or EUR 10 million in turnover should not be treated as a standalone test. In many sectors, medium-sized or large-enterprise status is the starting point, but the Act provides exceptions and separate qualification rules. The first step should therefore be to compare the organization’s actual activities with Article 5 and Annexes 1 and 2 to the KSC Act. 2.2 Key Entities and Important Entities: Differences in Requirements Key and important entities are generally subject to a similar set of obligations relating to risk management, incident handling and supply-chain security, subject to the exceptions provided for in the Act and sector-specific regulations. The primary differences concern the supervision and audit model. Under Article 15 of the KSC Act, a key entity must conduct a security audit at its own expense at least once every three years. The competent authority may order an external audit of a key entity at any time and of an important entity following a significant incident or another breach of the Act. 3. Is a NIS2 Audit Mandatory and When Should It Be Performed? Not every gap analysis offered on the market constitutes a statutory audit. The periodic audit obligation under Article 15 applies to key entities, while a voluntary gap analysis can help both key and important entities assess readiness, set priorities and gather evidence of compliance. A statutory audit must be conducted by an organization or by at least two auditors meeting the qualification requirements set out in Article 15(2), while complying with the independence requirement in Article 15(2a). 3.1 Key KSC 2.0 Deadlines in Poland Poland implemented the NIS2 Directive through the Act of 23 January 2026 amending the Act on the National Cybersecurity System and certain other acts (Journal of Laws of 2026, item 252). The Act was published on 2 March 2026, and its principal provisions entered into force on 3 April 2026. For entities that met the criteria for classification as a key or important entity on the effective date, self-registration in the KSC Register runs from 7 May to 3 October 2026, unless the entity is entered ex officio. Entities in this group should comply with the obligations in Chapter 3 no later than 3 April 2027. Key entities in this group must conduct their first statutory security audit by 3 April 2028. For entities brought within the scope of the Act at a later date or entered by administrative decision, the applicable deadline must be determined under the provision governing the relevant procedure. 3.2 How Often Should a Compliance Audit Be Repeated? Under Article 15 of the KSC Act, the statutory audit of a key entity must be conducted at least once every three years. Irrespective of that requirement, we recommend an annual internal compliance review and an additional assessment after any material change, such as an IT infrastructure upgrade, implementation of a new system, a significant incident or a change of a critical service provider. Security cannot be configured once and then forgotten. 4. Consequences of NIS2 Non-Compliance Failure to perform the obligations arising from the KSC Act implementing NIS2 may have serious consequences. These include supervisory measures, orders to remedy infringements and administrative fines. 4.1 Financial Penalties and Administrative Sanctions Entities that fail to perform their obligations under the KSC Act may be subject to supervisory measures and administrative sanctions. The Act provides for high maximum penalties and, where an infringement creates a particularly serious threat, a fine of up to PLN 100 million. Under Article 35 of the amending Act, the new penalties specified in that provision may first be imposed two years after the Act entered into force, generally from 3 April 2028. This does not postpone the deadlines for registration, implementation of obligations or incident reporting. 4.2 Management Liability and Reputational Risk Failure to perform statutory obligations may also result in a personal fine being imposed on the head of a key or important entity. Article 73a of the KSC Act provides for a fine of up to 300% of the person’s remuneration and, for certain public-sector entities, up to 100% of remuneration. The person regarded as the head of a particular entity depends on its legal form and governance structure. Irrespective of sanctions, an incident and disclosed negligence may also undermine the trust of customers and business partners. 5. What Does a NIS2 Audit Cover? This part of our work as auditors is particularly revealing because it shows precisely where organizations encounter the most common difficulties. Below, we describe the five areas in which we most frequently identify gaps during KSC 2.0 readiness projects, together with practical examples and the consequences of leaving them unresolved. 5.1 Unclear Accountability and Immature Risk Management The first thing we verify is who formally holds responsibility for cybersecurity within the organization. Our experience shows that unclear accountability is one of the most frequently identified issues. Roles across IT, security and management may be documented, yet in practice there is no unambiguous decision-making path for every type of significant incident. Valuable hours are then spent determining who is authorized to make a decision instead of responding to the incident. This issue is closely linked to immature risk management. Many organizations have a document entitled ‘Risk Management Policy’, but the assessment was performed only once and has not been updated since. Article 21 of the NIS2 Directive and Article 8 of the KSC Act require appropriate and proportionate technical, operational and organizational measures based on systematic risk management. If an organization cannot demonstrate a recurring process, it also lacks a reliable understanding of where it is genuinely most exposed. 5.2 Incomplete IT and OT Asset Inventory An incomplete or outdated inventory of IT and OT assets appears very frequently in our assessments. A typical example is a manufacturing company that declares full control over its infrastructure, yet during workshops no one can clearly state how many active servers it operates, which systems are outdated or which OT devices can access the corporate network. Without a reliable inventory, risk assessment becomes largely theoretical: an organization cannot assess the risk associated with an asset it does not know exists. During an incident, the team then loses time determining what has actually been compromised. 5.3 Untested Incident Response Procedures Our observations indicate that, in most organizations assessed, the incident response procedure existed only as documentation and had never been tested in practice. Article 23 of the NIS2 Directive and Article 11 of the KSC Act provide for multi-stage reporting: an early warning must be submitted without undue delay and no later than 24 hours after detecting a significant incident, followed by an incident notification no later than 72 hours after detection. The required reports must then be submitted, including a final report generally within one month of the incident notification. The procedure must therefore work at night, at weekends and when key personnel are unavailable. 5.4 Inadequate Business Continuity Plans An incident response procedure is not sufficient if the organization cannot maintain or restore critical services. In practice, we verify whether business continuity and disaster recovery plans cover critical dependencies, suppliers, backups, crisis communications and realistic recovery times. Article 21(2) of the NIS2 Directive and Article 8 of the KSC Act identify business continuity, backup management, disaster recovery and crisis management as elements of cybersecurity risk-management measures. A plan that has never been tested remains an assumption rather than evidence of resilience. 5.5 No Systematic Supplier Risk Assessment Supplier security management remains one of the greatest challenges. In the vast majority of organizations assessed by TTMS, there was no systematic evaluation of risks associated with service providers or partners that had access to the organization’s systems. Article 21(2)(d) of the NIS2 Directive and Article 8 of the KSC Act expressly cover supply-chain security. A typical example from our work is an external IT provider with remote access to company systems whose security controls have never been verified. An attack on such a partner can directly threaten the organization using its services. 5.6 Summary of the Five Most Common Gaps Area Observation from TTMS Projects 1. Accountability and risk management Frequently identified issue 2. IT and OT asset inventory Very frequent 3. Testing of incident response procedures Most organizations assessed 4. Business continuity Often requires additional testing and clarification 5. Supplier risk assessment The vast majority of organizations assessed High-risk gaps identified in a single audit Usually between one and several The data in the table consists of anonymized qualitative observations from gap analyses and audits conducted by TTMS in 2025–2026. It is not a representative market study. 7. How a NIS2 Audit Works: Step by Step Below, we explain how we conduct a NIS2 audit for a client, step by step, from the initial contact through to the completed remediation roadmap. Step 1: Determine Whether the Organization Is Subject to KSC 2.0 The first step is to establish whether the organization is subject to the KSC Act and whether it qualifies as a key or important entity. This determination defines the subsequent scope of the assessment and the obligations that must be considered. Step 2: Questionnaire and Baseline Data Collection We then conduct a detailed questionnaire and collect baseline information from the IT, security and management teams. This allows us to build an initial picture of the organization’s security posture before examining the documentation in detail. Step 3: Review of Documentation and Processes The next stage involves reviewing the documentation and existing processes, comparing what is written on paper with what actually happens within the organization. This is where the discrepancies described earlier most often become visible, such as an incident response procedure that exists but has never been tested. Step 4: Workshops and Team Interviews We conduct workshops and interviews with employees from different departments because documentation rarely tells the whole story. A conversation with a network administrator or the person responsible for supplier relationships often reveals more than a formal review of documents. Step 5: Findings and Recommendations Report At the end of the assessment, we prepare a detailed report presenting the findings and specific remediation recommendations in language that is understandable not only to IT, but also to the organization’s management. The head of the entity and the relevant governing bodies are responsible for approving and overseeing implementation of the measures to the extent required by the Act and the entity’s governance structure. Step 6: Remediation Roadmap The final report includes a prioritized remediation roadmap. In practice, we typically identify between one and several high-risk non-compliances during a single audit. The roadmap is therefore not about implementing every recommendation at the same time, but about sequencing activities to reduce the most significant business risks as quickly as possible. 8. How to Prepare Your Organization for a NIS2 Audit Preparing for a NIS2 audit requires involvement from every department, not only IT. It is worth collecting current security policy documentation, a list of systems and external suppliers, and appointing a person to act as the auditors’ primary point of contact. The better prepared the organization is at the outset, the faster and more efficiently the process can be completed, reducing both cost and pressure on the team. 9. NIS2 Audits and Other Security Audits: Key Differences A NIS2 and KSC 2.0 compliance assessment differs from other security reviews because it addresses specific regulatory obligations arising from the Act on the National Cybersecurity System. ISO/IEC 27001 certification is generally voluntary, while a GDPR compliance audit focuses on personal data protection obligations. These scopes may partially overlap, but none of them automatically replaces an assessment of compliance with KSC 2.0. 10. Benefits of Commissioning a NIS2 Audit from TTMS TTMS is a global IT company specializing in the implementation and maintenance of bespoke IT systems, business process automation and outsourcing services. With experience in systems integration, Salesforce, Microsoft and AEM implementations, as well as IT service management, our consultants understand not only regulatory requirements but also the real-world IT infrastructure architectures our clients operate. 10.1 Scope and Delivery of Our Service We provide a comprehensive NIS2 and KSC 2.0 readiness and gap assessment covering all the areas described above: from asset inventory, risk management and incident response procedures to supply-chain security. We follow a proven process, starting with an initial questionnaire, continuing through team workshops and concluding with an actionable roadmap. If the engagement includes a statutory audit under Article 15, the scope, auditor qualifications and independence requirements must be confirmed separately. 10.2 Support with Implementing Post-Audit Requirements The real value of an audit lies in implementing its recommendations, not merely producing a report. After completing projects, we observe that clarifying accountability, updating documentation and implementing remediation measures shorten incident response times, improve asset records and reduce the number of non-compliances found during subsequent reviews. Our support includes security process automation, integration of monitoring systems and development of procedures that work in teams’ day-to-day operations. 11. Contact a TTMS Expert and Prepare Your Organization for a NIS2 Audit 11.1 Make Sure Your Organization Is Ready for KSC 2.0 KSC 2.0 readiness is difficult to assess from documentation alone. The key is to verify whether responsibilities, processes and safeguards work in practice and whether the organization can demonstrate compliance during an audit or inspection. If you would like to discuss your organization’s situation, contact TTMS experts. We will help determine which areas require verification, what audit scope is appropriate and where preparations should begin. We will tailor the engagement to the entity’s status and its obligations under KSC 2.0. 12. Legal Basis and Sources Directive (EU) 2022/2555 of the European Parliament and of the Council (NIS2), in particular Articles 20, 21, 23, 32 and 33; the Act of 5 July 2018 on the National Cybersecurity System, as amended by the Act of 23 January 2026 (Journal of Laws of 2026, item 252), in particular Articles 5, 8, 11, 15, 73 and 73a and Annexes 1 and 2; Articles 33–35 of the amending Act; and communications from the Polish Ministry of Digital Affairs concerning the KSC Register and the S46 System. The legal status and implementation timeline were verified on 13 July 2026. 13. FAQ Is a Gap Analysis the Same as a Statutory KSC Audit? No. A gap analysis is a voluntary readiness assessment that helps identify deficiencies and prioritize actions. A statutory security audit under Article 15 of the KSC Act must meet the requirements relating to scope, auditor qualifications and independence. What Is a NIS2 Compliance Audit? A NIS2 compliance audit is a market term for an assessment process that verifies an organization’s readiness for the requirements of the NIS2 Directive and the KSC Act. It may cover IT systems, risk management and incident response. However, not every such review constitutes a statutory security audit under Article 15 of the KSC Act, which must meet the applicable requirements concerning scope, auditor qualifications and independence. What Does NIS2 Involve? NIS2 is an EU directive that introduces rigorous network and information systems security requirements for organizations in key and important sectors. Its purpose is to harmonize security standards across the European Union and strengthen resilience against cyberattacks. How Much Does a NIS2 Audit Cost? The cost of a NIS2 audit depends on the size of the organization, the number of systems and locations covered by the review, and the scope of support required to implement the recommendations. An accurate quotation can be provided after a short initial discussion in which we establish the actual scope of work.
Read
What is reporting in business intelligence and how it can help your organization
In most companies today, data is everywhere: in CRM, ERP, financial systems or marketing tools. The problem is usually not the lack of them, but the fact that it is difficult to quickly answer a simple question: “what actually happens in business?”. However, access to data alone is not enough to make the right decisions. The biggest challenge is to translate them into concrete conclusions and actions. This is where Business Intelligence (BI) reporting helps. BI reporting has ceased to be the domain of IT departments only and has become one of the key competencies of modern organizations. Whether you’re a CFO analyzing quarterly performance or a marketing manager evaluating campaign performance, BI reports provide a structured, transparent, and actionable view of your data. With clear visualizations and analytics, they allow you to spot trends, identify problems, and make better business decisions faster – much more effectively than traditional spreadsheets. 1. What is BI reporting? BI reporting is about transforming raw, distributed operational data into clear insights that support fact-based decisions. It’s a structured process that involves pulling data from multiple sources, modeling it, and presenting it in the form of reports and analytics dashboards that are available to different teams in the organization. At TTMS, we look at Business Intelligence reporting not just as a technical task, but as a comprehensive analytical capability of an organization. It involves integrating data from multiple systems, building a semantic data model, ensuring proper management and security, and then sharing reports across workspaces, applications, and embedded analytics. The goal remains the same: to help organizations monitor performance, identify trends, and respond quickly to changes using up-to-date information instead of static spreadsheets. BI reports can take various forms: from management dashboards, through operational reports, to detailed analyses supporting specific areas of the business. They help teams at every level of the organization better understand what’s going on, why it happened, and what actions are worth taking next. 2. BI Reporting vs. Traditional Reporting: How Are You Different Traditional reporting usually focuses on the analysis of historical data. The data is exported from the system, organized in a spreadsheet, and then made available as a static file showing the situation at a specific point in time. By the time the team takes action on it, the information may already be out of date. BI reporting works differently. Instead of relying on isolated data sets, a BI system integrates information from multiple sources into one consistent, regularly refreshed model. Users can access up-to-date reports, apply filters, drill down into detailed data, and analyze information on their own without waiting for a new IT statement. This shift from passively receiving reports to actively exploring data is changing the way organizations work with information. The data becomes not only a summary of what has already happened, but a real support in making faster and more accurate decisions. 3. BI Reporting vs Business Intelligence: Where the Line Lies BI reporting and business intelligence are often used interchangeably, but they don’t mean exactly the same thing. BI reporting is primarily descriptive and diagnostic. It helps answer the questions: “what happened?” and “why did this happen?”, presenting historical and current data in a readable, structured form. Business analytics goes one step further. It also includes predictive and prescriptive analysis, which helps predict future events and indicate possible actions. BI reporting can show that the number of departing customers increased in the last quarter. Predictive analytics will help determine which customers may leave in the next month, and prescriptive analytics will tell you what actions to take to prevent this. Both approaches complement each other. A well-designed BI infrastructure creates a foundation on which to build more advanced analytics and make decisions based not only on what has already happened, but also on what may happen in the future. 4. Basic elements of a BI reporting system A modern BI reporting system is much more than a set of charts and tables. It is a layered architecture of interconnected components, each of which is responsible for a different stage of working with data – from its download, through organizing and securing, to presenting it in the form of clear reports. Such a system consists of, among others, data sources, integration processes, data model, security layer, visualization tools and report distribution mechanisms. Only when they are combined can you provide reliable and actionable information to the right people at the right time. In practice, the problem begins when sales, finance, and operations count the same KPI in three different ways. A good BI environment should sort out this chaos. This allows sales, finance, operations, and marketing teams to work on the same definitions, metrics, and reports, rather than creating their own versions of the truth in separate spreadsheets. It is also worth checking right away whether the solution will not stop at the first 50 users or when connecting another source system. A BI reporting system should grow with the organization: support new data sources, new users, new business areas, and increasingly advanced analytics needs. 4.1. BI Reports BI reports are structured statements that analysts, managers, and executives use to monitor performance and make business decisions. Unlike simply exporting raw data, a BI report is designed with specific audiences, their needs, and goals in mind. It can include calculated metrics, comparisons, filters, data slices, and visuals that help you quickly understand the most important information. This means that you don’t have to analyze big data on your own or build your own reports from scratch. A BI report can be a simple, one-page summary of key KPIs or an extensive, multi-page analytical report with the ability to drill down into detail. Its scope and level of complexity should always result from the real needs of the recipients and the decisions that the report is intended to support. 4.2 Dashboards The main point of contact for users with the BI system are dashboards. They provide a quick overview of key performance indicators by consolidating key metrics into a single, interactive view. A well-designed dashboard doesn’t try to show everything at once. Instead, it presents the right information at the right level of detail, with a clear visual hierarchy. This allows users to quickly spot problems, deviations from the goal, trends, and potential business opportunities. Modern dashboards are increasingly tailored to specific roles in the organization. A CEO may need a synthetic view of strategic KPIs, while a regional sales manager will use a more operational view of performance, sales funnel, or meeting goals in a given region. Both people can work on the same data model, but receive information presented in a way that suits their tasks and responsibilities. 4.3 Data visualization Data visualizations translate numbers into forms, colors, and layouts that the human brain processes faster than lines of text or complex tables. Charts, maps, scatter diagrams, and heat maps help you see the structure of your data: trends, anomalies, dependencies, and outliers that might go unnoticed in the table. Well-designed visualizations are one of the key elements of an effective BI platform. They are not only used to present data aesthetically, but above all to understand it. Thanks to interactivity, users can filter information, analyze details and discover dependencies on their own, instead of just passively reading ready-made statements. 4.4. OLAP and Ad Hoc Queries OLAP, or Online Analytical Processing, enables multidimensional analysis of data in different cross-sections at the same time. In practice, this means that you can analyze, for example, revenue by region, product category, sales channel and period within one consistent model. Ad hoc queries complement this functionality by allowing business users to ask new questions without having to wait for the next report to be prepared by the IT department. Thanks to this, data analysis becomes more flexible and better suited to the current needs of the business. When self-service data exploration is based on an ordered semantic model, your organization gains the best of both worlds: central control over metric definitions and the freedom for different teams to analyze data. This allows you to maintain reporting consistency while speeding up decision-making. 5. Types of Business Intelligence Reports Not all BI reports have the same function. Organizations use a practical division of reports according to their recipients, time horizon and the type of questions they are supposed to answer. Operational reports support the daily work of teams. They are based on data that is refreshed frequently or almost in real time. They can help the warehouse manager monitor inventory levels and the call center leader track the wait time of customers in the queue. Strategic reports are designed with management and a long-term decision-making perspective in mind. They typically span quarters or years, focusing on revenue trends, segment profitability, business objectives, and market changes. Analytical reports are more exploratory in nature. They help you understand the causes of phenomena, test hypotheses, and analyze relationships, for example, through cohort analysis, sales funnel analysis, or root cause analysis. A separate category is self-service BI, which is tools and environments that allow business users to create queries, reports, and visualizations on their own without the constant involvement of the IT department. This direction is becoming increasingly important as organizations expect faster access to information and greater independence for teams to work with data. Self-service BI works best when it’s based on an ordered semantic model and certified datasets. This allows companies to reduce the bottleneck on the part of analysts while maintaining consistency in definitions, data quality, and reporting reliability. 6. Examples of the use of Business Intelligence in different departments of the organization BI reporting is not a tool for one department. Each feature makes data-driven decisions, and real-world implementations show what is truly achievable. For example, a mid-sized healthcare provider in the U.S. implemented a centralized reporting solution based on Power BI, which replaced the operational reporting previously conducted in spreadsheets. The preparation time for monthly reports has been reduced from about 5 days to less than half a day, or about 90%. On the other hand, management queries that had previously been answered for several days could be handled on the same day. Similar effects can be achieved in the manufacturing sector. One manufacturing company has rebuilt its reporting in Power BI, by introducing automatic data refresh and standardized reporting models. As a result, the reporting time at the end of the month was reduced by 60-70% and the costs of overtime related to manual data preparation and merging were significantly reduced. A professional services company that integrated Power BI with CRM, PSA, and financial systems reduced the time it takes to prepare weekly reports on resource utilization and pipeline by 30-40%. Access to near-current data on billing hours also allowed for better monitoring of the level of consultant utilization and faster response to deviations. This translated not only into time savings, but also into a real impact on revenues. In practice, the greatest value of BI reporting is not the mere reduction of manual work. More importantly, however, the organization can make more accurate decisions faster based on current, reliable data. On the infrastructure side, retail and e-commerce organisations benefiting from Snowflake and Power BI achieve a 20-25% cost reduction for analytical computing by separating BI workloads into a dedicated virtual warehouse with auto-suspend functionality. This approach has also improved the responsiveness of dashboards during peak hours, as BI queries have stopped competing for resources with data retrieval and processing processes. The effect was twofold: lower infrastructure costs and a more stable user experience using reports and analytics dashboards. TTMS cooperated with customers who faced similar issues related to data fragmentation: multiple disconnected source systems, inconsistent metric definitions across departments, and reporting cycles counted in days rather than hours. The repeatable pattern is clear here: a well-managed Power BI semantic model, properly integrated into the customer’s data environment, solves the problem of metric consistency first, and only then saves time. In one such project, consolidating reporting under a single managed model eliminated conflicting margin definitions that previously led to recurring disputes between finance and commercial teams. Sales and marketing teams use BI dashboards to connect spend to pipeline performance and revenue. This replaces distributed reporting in spreadsheets with one consistent view that updates automatically. In each case, the basic mechanism remains similar: manual, fragmented reporting is replaced by a connected and managed BI layer. This not only saves time, but also improves the quality of decisions made based on data. 7. Key Benefits of BI Reporting The business case for investing in BI reporting is confirmed by independent market research. Study The Total Economic Impact™ of Microsoft Power BI conducted by Forrester Consulting showed a 366% return on investment (ROI), a 2.5% increase in operating revenue, and 125 hours of savings per year for each BI user. At the same time, the workload of analytical teams decreased by 42%. In practice, most organizations see the benefits of BI in three places: faster decisions, less manual work, and greater trust in data. The first is better decision-making. When leaders have access to up-to-date, reliable, and structured data, they can assess the situation faster, identify risks, and choose actions based on facts rather than intuition. The second important benefit is greater operational efficiency. Automated data flows reduce the time previously spent manually retrieving, combining, and formatting information. This allows teams to focus on analysis and recommendations instead of preparing subsequent versions of spreadsheets. BI reporting also supports organizational cohesion. Common dashboards, standardized metrics, and a single data model keep different departments working on the same version of the truth. This reduces data accuracy disputes and allows you to focus on making business decisions. Finally, BI strengthens strategic planning. Access to trend data, segmentation, and scenario analysis helps executives spot opportunities and threats earlier. That’s why organizations are increasingly treating BI reporting not only as an analytical tool, but also as a way to standardize decision-making processes, improve management, and reduce costly disparities between departments. 8. The biggest challenges of BI reporting and the causes of project failures The path to effective BI reporting is associated with real obstacles. Therefore, it is worth talking directly about why BI initiatives fail, instead of limiting ourselves to a general list of potential challenges. Research on the failure of BI projects in enterprises consistently points to two layers of problems. The first includes strategic errors: unclear business goals, poor support from the board of directors, or the lack of an owner responsible for defining key metrics. The second concerns the implementation of the project itself: low data quality, uncontrolled expansion of the scope of work and insufficient training of users. According to available analyses, 57% of BI deployments exceed budget or schedule due to lack of control over the scope of the project, and 55% of users do not trust BI tools due to insufficient training. Problems related to data management are particularly harmful. Gartner warned that by 2027, 80% of data governance initiatives will fail, and the cause will most often be a lack of responsibility on the part of the business, not the technology itself. When no one is responsible for clearly defining terms such as “revenue”, “margin” or “active customer”, each team begins to understand them differently. As a result, trust in the BI platform decreases, regardless of how well the data model is designed. This is one of the most common barriers that TTMS observes in organizations investing in BI tools but not achieving the expected adoption. Another recurring pattern of failure is starting a project with the choice of a tool rather than deciding which reporting you want to support. Organizations that create dashboards before defining business questions, decisions, and expected outcomes often end up with reports that look impressive but don’t change the way teams operate. BI built around available data, and not around important decisions, becomes a reporting exercise, not a real decision support system. It is the prioritization of results rather than effects that is one of the most frequently cited causes of failure in practitioners’ research and analytical literature. TDWI Survey they also point to the complexity of data integration as a major technical hurdle. Organizations that underestimate the difficulty of connecting legacy systems, SaaS applications, and distributed databases often encounter months of delays in BI projects. The source of these delays are integration works that have never been properly planned. Competence gaps further reinforce this problem. TDWI’s benchmark research indicates that the chronic shortage of BI specialists, data engineers, and analytical translators remains a permanent constraint for organizations looking to develop or modernize their BI capabilities. The solutions are structural. Establishing clear responsibility for metrics before choosing a tool, including data governance in the first sprint instead of treating it as a second-phase task, and matching BI investments to the actual level of maturity of the organization significantly increase the chances of successful implementation. 9. How to Build an Effective BI Reporting Strategy A BI reporting strategy that delivers long-term business value requires more than choosing the right tool and loading data. In projects that develop over several years, BI usually ceases to be an “implementation”. It becomes a product that is developed similarly to a business application – with a backlog, owner and subsequent iterations. This approach requires clearly defined business goals, appropriate data management policies, and continuous improvement of reports and analytics models. It is also crucial to define responsibilities for metrics, data quality, and the development of the BI environment. This allows reporting to evolve with the changing needs of the organization, rather than quickly losing relevance. The most effective BI strategies assume continuous iteration from the beginning. Reports are regularly evaluated for their relevance, and new business needs are gradually incorporated into data models and dashboards. Thanks to this, the reports do not end up as nice dashboards that no one looks into. They become a tool for making specific decisions. 9.1. Define goals and success metrics before you start working with data The first and most important step is to determine what success looks like before an organization opens up any BI tool. It is worth pointing out three to five decisions or processes with the greatest impact on the business that need improvement. This can be pricing policy, customer churn reduction, delivery planning, sales pipeline management, or financial closing process. For each of these areas, you need to determine how BI reporting can realistically improve outcomes. It’s best to put it as a value hypothesis, based on measurable KPIs. This allows an investment in BI to be evaluated with the same accuracy as any other business initiative. TDWI’s research shows that many organizations don’t have a clearly defined data and analytics strategy at the enterprise-wide level. This leads to ad hoc BI projects, inconsistent tools, and duplication of the same reporting activities across different teams. Starting with clearly defined goals helps avoid this fragmentation. 9.2. Data environment audit and organization maturity assessment Before designing any BI solution, it’s a good idea to reliably assess the current state of your data environment. Such an audit should include data quality, completeness of integration, maturity of management rules, organizational structure and team competencies. In organizations with a lower level of maturity, the priority should be the basic foundations: data integration, creating a single version of the truth, and implementing key KPI dashboards. Only on this basis can more advanced reporting and analytical capabilities be safely developed. In organizations with higher maturity, the scope of activities may include advanced analytics, self-service BI, and reporting embedded in business applications. Trying to skip earlier stages often leads to costly errors, low adoption, and a lack of trust in data. 9.3. Choose a BI tool that fits your organization’s needs Tool market Business Intelligence it is mature and very competitive today. Among the most frequently chosen platforms for large organizations, Microsoft Power BI, Tableau, Qlik and Cognos are regularly mentioned. Each of these solutions offers slightly different capabilities in terms of self-service analytics, data management, integration into the corporate ecosystem or the use of AI-based features. TTMS supports customers in building modern analytical environments, using Microsoft Power BI as part of a partnership with Microsoft and the Snowflake platform as a data storage and processing layer. This approach allows you to create a consistent environment covering the entire process – from the collection of raw data, through its integration and modeling, to interactive reporting and business analysis. The choice of the right BI tool should primarily result from the needs of the organization. It is worth evaluating the ease of use for target users, the ability to integrate with existing systems, the level of security and data access management, the scalability of the solution, and the availability of AI-supported features. Data governance mechanisms and consistency in metric definitions are also becoming increasingly important. In modern BI environments, they are no longer additional features, but one of the key criteria for choosing a platform. It is these data that determine whether an organization will be able to build trust in data and use it effectively in the decision-making process. 9.4. Design reports with your audience, not just your data in mind A technically correct report that no one uses is still a failure. That’s why BI reports should be designed around the specific decisions they’re meant to support, rather than just around the data available in the organization. Executives need a synthetic view of trends and key KPIs. Operations teams expect quick access to up-to-date information about the current situation. Analysts, on the other hand, need the ability to drill down, filter data, and explore on their own. Efficiency is also an element of a good reporting project. Users expect dashboards to respond quickly, and response times will be counted in single seconds rather than long waits for a view to load. If a report is slow, its adoption decreases, even if it contains valuable data. 9.5 Manage, monitor, and continuously optimize your BI environment BI management is an ongoing practice, not a one-time task performed at the beginning of a project. It includes defining and enforcing common metrics, managing role-based access, tracking data lineage, auditing report usage, and deprecating content that has become outdated or duplicates existing solutions. One of the most effective structures supporting the long-term quality of reporting is the BI Center of Excellence, which is a small, cross-functional team responsible for standards, good practices, user support and management of the BI environment. Data on the use of reports should feed the BI development backlog. This allows the organization to prioritize critical improvements, remove repetitive reports, and respond faster to changing business needs. 10. BI Reporting Best Practices for 2026 The most important BI reporting practices for 2026 reflect a broader shift in the approach to analytics. Organizations are moving away from passive dashboards created mainly by IT departments in favor of analytical environments supported by AI, self-service and real business decision-making needs. Five practices are particularly important. The first is to treat BI as a managed self-service product. This means building a central analytics platform with a product owner, backlog, and roadmap, while providing business users with the ability to create analytics on their own based on certified and managed datasets. The second practice is to standardize the semantic model and the reusable metrics layer. When terms such as “revenue,” “customer churn,” and “active customer” are defined once and used consistently across the organization, the company reduces data fragmentation and strengthens trust in reporting. The third practice is to embed AI-powered analytics into key workflows. Natural language queries, automatic anomaly detection or analysis of the main factors influencing results are no longer an experiment, and are becoming an expected element of modern BI implementations. As the TTMS points out in its analysis on the AI in business, 2026 will be a period of greater responsibility for investments in artificial intelligence. Experiments conducted between 2023 and 2025 must translate into measurable business results, stable management and greater cost discipline. The same direction will also affect the development of BI environments. The fourth practice is to design BI around decisions and actions, not the dashboards themselves. Reporting should be as close to day-to-day operational processes as possible to shorten the gap between gaining insight and taking action. The fifth practice is user-centered design. Performance, availability, responsiveness, and convenience of cross-device reporting should be considered as basic requirements, not add-ons. Even the best-designed visuals won’t increase adoption if the reports load too slowly or are difficult to use on a daily basis. 11. How TTMS can help with BI reporting For organizations that are in the early stages of BI implementation, TTMS starts with the foundations: data integration, structured semantic model, and KPI reporting. The goal is to create a single version of the truth on which the effectiveness of all subsequent analytical activities depends. For organizations ready to scale, TTMS expands the BI environment with self-service layers, role-aligned dashboards, embedded analytics, and Snowflake-based data warehouses. This approach allows you to separate BI workloads, improve reporting efficiency, and better control infrastructure costs. At every stage, TTMS combines technical competence with experience in change management. This helps to reduce the gap between a well-designed BI system and the solution that users actually use in their daily work. Talk to a TTMS BI professional about your current data environment and check where to start. What is BI reporting and how is it different from regular reporting? BI reporting is the process of collecting, organizing, modeling, and presenting data in the form of interactive reports and analytics dashboards. Its goal is to support business decisions based on up-to-date, consistent and reliable information. Unlike traditional reporting, which often relies on static statements and manually prepared sheets, BI reporting integrates data from multiple sources into one regularly refreshed model. This allows users not only to read the results, but also to filter the data, analyze details, and search for answers to subsequent questions on their own. What is Business Intelligence reporting used for? Business Intelligence reporting is used to monitor performance, track KPIs, identify trends, and support business planning. It helps organizations better understand what is happening in sales, finance, marketing, operations, customer service, or other areas of business. In practice, BI reporting can support both day-to-day operational decisions and long-term strategic planning. It all depends on how the data model is designed, what reports will be made available to users, and what decisions you want to make with them. What do BI reports mean for business users? For business users, BI reports mean access to up-to-date, trusted data in a form tailored to their role and daily decisions. They don’t need to know SQL, data architecture, or the technical details of source systems to use valuable insights. A well-designed BI report allows managers, specialists, and team leaders to independently analyze results, check for deviations, filter data, and react faster to changes. In many cases, it gives business users analytical capabilities that previously required the support of a dedicated analyst. How to implement BI reporting in a company? Successful BI reporting implementation starts with defining business goals and success metrics. Next, it’s a good idea to audit your existing data, choose the right platform, build a structured semantic model, and design reports with specific audiences in mind. Equally important are the processes of management, security, monitoring of data quality and continuous optimization. TTMS supports organizations at every stage of the process—from Power BI deployment and Snowflake, to data integration and report design, to training, user adoption, and managed services. What are the most commonly used BI reporting tools? Some of the most commonly used BI reporting tools include Microsoft Power BI, Tableau, Qlik, Cognos, and data platforms such as Snowflake, which support storing, processing, and sharing data for analytics. The choice of tool should depend on the needs of the organization, the existing infrastructure, security and management requirements, the number of users, and the level of complexity of reporting. The platform alone is not enough – data quality, a consistent semantic model, the right metrics and real adoption on the part of business users are also crucial.
Read
AI and business process automation with Webcon BPS
Companies that only a few years ago treated automation as a project "for the future" are now facing real competitive pressure. Platforms such as WEBCON BPS have ceased to be a niche solution for technology pioneers, and have become a proven tool for implementing AI and automating business processes on an organization-wide scale. The question is no longer "whether to automate", but "where to start and how to do it effectively".
Read
Low-code AI Adoption in Pharma: 2026 Guide
Pharmaceutical companies have always faced intense pressure to move faster, spend less, and stay compliant. What’s shifted recently is the nature of the tools available to meet those demands. Low-code AI adoption in pharma is no longer a fringe concept explored by forward-thinking R&D labs. It’s becoming a practical strategy for organizations that need to digitize operations quickly, without building every solution from scratch. This guide is written for pharma IT leaders, digital transformation managers, and compliance officers who want a clear, realistic picture of where low code AI stands in 2026 and how to use it effectively across the life sciences value chain. 1. Why low-code AI is gaining traction in Pharma right now The pharmaceutical sector has historically been slow to adopt new technology, and for good reason. Regulatory obligations, data sensitivity, and patient safety create a conservative environment. But that conservatism carries an increasingly steep price. The global low-code and AI-assisted workflow automation platform market is projected to grow strongly, with Technavio estimating a 32.2% CAGR between 2025 and 2029. For pharma and life sciences organizations, this growth reflects a broader shift toward faster, more governed digitalization of complex workflows. The pressure to digitize isn’t letting up, and the gap between what pharma organizations need to deliver and what their IT teams can realistically build keeps widening. 1.1 The pressure driving faster digital adoption across the life sciences value chain Regulatory demands are intensifying globally. At the same time, operational costs are climbing, and the time between molecule identification and market approval remains under constant scrutiny. Companies face mounting expectations from regulators, patients, and investors to do more with their data, and to do it faster. Traditional software development cycles, often spanning years, simply can’t keep pace. Digital transformation has moved from a strategic priority to an operational necessity. Pharma companies that can’t rapidly digitize clinical data workflows, manufacturing quality processes, or pharmacovigilance functions are accumulating technical debt that compounds every year. 1.2 What low code AI actually means in a pharma context Low code AI refers to platforms that let users build functional, AI-assisted applications through visual interfaces, drag-and-drop tools, and pre-built templates, rather than writing extensive custom code. In a pharma context, this means a quality assurance manager could configure a deviation management workflow, or a clinical operations team could build a data collection form, without waiting months for a development sprint. Two platforms that illustrate this well in enterprise pharma environments are Microsoft Power Apps and Webcon BPS, both of which TTMS implements and supports for regulated industries. Power Apps enables rapid digitization of business processes across departments, while Webcon BPS provides structured workflow automation with a strong focus on compliance and process governance. 1.3 How it differs from traditional AI and full-code development for regulated environments Traditional AI development in pharma typically requires dedicated data science teams, significant infrastructure investment, and long validation cycles. Full-code development offers maximum flexibility but demands specialized developers, extensive documentation, and project timelines that can stretch well beyond what business stakeholders actually need. Low code AI sits between these extremes. It provides enough flexibility to address real business problems, with enough structure to satisfy governance requirements. Crucially, it reduces dependency on highly specialized engineers while still producing auditable, maintainable applications. For regulated environments where every system change requires documented rationale, that balance matters enormously. 2. Key benefits of low code AI adoption in pharma The case for low code AI automation in pharma isn’t theoretical. The concrete operational gains it delivers across the organization, from IT governance to the shop floor, are what make it worth pursuing. 2.1 Speed to deployment: from months to weeks The most immediate advantage is compressed development timelines. Pharma supply chain applications built on low code platforms have demonstrated up to 75% faster development cycles compared to traditional coding approaches, enabling quicker time-to-market for both drugs and supporting applications. In pharmaceutical manufacturing, where process changes need to respond to audit findings or regulatory updates quickly, that speed is operationally significant. This isn’t about cutting corners. It’s about removing the structural inefficiencies that slow traditional development: handoffs between business and technical teams, lengthy requirements documentation cycles, and redundant testing phases. Low code platforms encode many of those quality standards directly into the build environment. 2.2 Empowering citizen developers without sacrificing it governance One of the most practically valuable aspects of low code AI is what it does for non-technical staff. Citizen developers, business users with limited or no formal coding background, can build applications that automate their own workflows. This doesn’t mean IT steps aside; it means IT shifts from writing code to governing platforms, setting standards, and ensuring security. TTMS’s Microsoft Power Apps consulting service is built around exactly this model. By implementing Power Apps within a governed Microsoft Power Platform environment, TTMS enables pharma teams to develop functional apps in their own domain while IT retains control over data connections, compliance configurations, and deployment permissions. Fewer bottlenecks, faster delivery, and IT resources freed for higher-complexity challenges. 2.3 Reducing costs across the pharma value chain Custom software development at enterprise scale is expensive. Beyond developer salaries, costs accumulate in vendor licensing, integration work, project management, and ongoing maintenance. A Forrester TEI low-code study cited by Pega found 598% ROI and $12.5 million in productivity savings over three years for enterprises using Pega’s low-code platform. While this is not pharma-specific, it illustrates the type of financial impact low-code programs may deliver when implemented at scale. For organizations managing dozens of operational systems across manufacturing sites, clinical operations, and regulatory affairs, low code platforms consolidate much of this expense through reusable components, pre-built connectors, and simplified update cycles. 2.4 Maintaining compliance in a low code build environment Compliance is where pharma organizations most commonly hesitate on low code. The concern is legitimate: how do you ensure that applications built by non-developers meet GxP standards, maintain audit trails, and support validation documentation? The answer lies in choosing the right platform and the right implementation partner. TTMS’s Webcon BPS implementation service is specifically designed to address this. As an official Webcon Partner, TTMS deploys Webcon BPS in ways that embed process governance, version control, and audit trail functionality directly into workflow design. Rather than retrofitting compliance onto finished applications, compliance is part of how the application is built from the start. This approach aligns well with the documentation and validation requirements that pharma quality teams manage daily. 3. High-impact use cases across the pharma value chain Low code AI adoption in pharma isn’t limited to a single department or function. Its real value emerges when applied consistently across the value chain, each use case building on the organization’s growing low code maturity. 3.1 Accelerating drug discovery and r&d workflows In early-stage research, scientists spend a significant portion of their time on data entry, status tracking, and reporting. Tasks that add little scientific value but consume hours. Low code platforms can automate these workflows, connecting laboratory information systems with project management tools and enabling AI-assisted data analysis through pre-built connectors to services like Azure AI. TTMS’s background in AI implementation and IT system integration makes this kind of layered solution achievable. A Power Apps-based research tracking application, integrated with existing LIMS and ERP systems, can give R&D teams real-time visibility into experiment status, resource allocation, and milestone progress, without commissioning a full custom development project. 3.2 Improving quality control and compliance in pharmaceutical manufacturing AI in pharmaceutical manufacturing is increasingly focused on anomaly detection, deviation management, and real-time quality monitoring. Low code platforms enable quality teams to build and maintain these workflows themselves, reducing the time between identifying a process gap and deploying a digital solution. Webcon BPS is particularly well-suited here. Its process-centric architecture supports structured deviation workflows, corrective and preventive action tracking, and batch release sign-off processes, all with built-in audit trails that align with GxP documentation expectations. For manufacturers operating across multiple sites, the ability to standardize these processes on a single governed platform is a meaningful operational improvement. 3.3 Streamlining clinical trial data management Clinical trials generate enormous volumes of data from diverse sources: electronic data capture systems, wearables, site management software, and patient-reported outcome tools. Managing this data consistently while maintaining regulatory compliance is a persistent challenge for clinical operations teams. The potential gains here are substantial. Seagen, a biopharmaceutical company, deployed a cloud-native solution to automate clinical trial data publishing and legal/compliance review workflows that previously took up to six months to complete. By integrating the clinicaltrials.gov API directly into their review process, the team reduced approval time from months to minutes. Pfizer’s integration team later recognized the solution as best-in-class, noting that their own equivalent process required six months to approve just three to five trials. It’s a concrete illustration of what targeted automation can achieve in regulated clinical workflows. The same architectural thinking applies when deploying low code AI tools for data aggregation dashboards, automated status reporting, and anomaly-flagging workflows across trial operations. 3.4 Enhancing pharmacovigilance and post-market surveillance Pharmacovigilance requires rapid intake, triage, and reporting of adverse event data. Delays carry both regulatory and reputational risk. Low code AI tools can automate case intake forms, route reports to the correct reviewers, and generate draft narratives using AI assistance, all within a governed workflow that maintains a complete audit trail. Webcon BPS’s workflow architecture maps naturally to the structured, multi-step review processes that pharmacovigilance teams rely on. Combined with TTMS’s experience in IT outsourcing and managed services, organizations can deploy and maintain these solutions without building internal platform expertise from scratch. 3.5 Optimizing supply chain visibility and logistics Pharmaceutical supply chains are complex, tightly regulated, and vulnerable to disruption. Low code AI platforms can surface real-time inventory data, automate reorder triggers, and provide visibility into cold-chain compliance status through dashboards that operations teams can configure and update themselves. Quest Nutra Pharma partnered with Kissflow adoption of a low-code compliance workflow platform is a useful example. By automating quality check tracking, regulatory process updates, and compliance reporting on a single governed platform, the company achieved faster response times when adapting to regulatory changes and reduced non-compliance risk across its operations. Power Apps, connected to enterprise data sources through Power Platform’s broad connector library, offers the same capability for mid-sized pharma companies that need more than a spreadsheet but can’t justify a major ERP customization project. 4. Choosing the right low code ai platform for life sciences Platform selection is where many pharma organizations stall. The market includes dozens of low code tools, and not all of them are suited to the compliance, security, and integration demands of a regulated industry. A structured evaluation process helps narrow the field considerably. 4.1 Core capabilities to evaluate for pharma-specific requirements Any platform evaluation should start with the functional requirements most critical to pharma operations: structured workflow support, role-based access control, document handling, electronic signatures, and AI integration. Beyond features, consider the governance model. Can IT teams set guardrails for what citizen developers can build? Can platform administrators enforce data classification rules? These controls aren’t optional in an environment where data integrity is a regulatory requirement. 4.2 Integration with legacy systems and existing data infrastructure Pharma organizations carry significant legacy system burden. ERP platforms, LIMS, document management systems, and clinical data repositories have often been in place for decades, each with its own data model and integration interface. A low code platform that can’t connect to these systems reliably adds integration risk rather than reducing it. Both Power Apps and Webcon BPS address this challenge directly. Power Apps connects to hundreds of enterprise systems through Power Platform connectors, while Webcon BPS provides REST API support and native integrations with common business systems. TTMS’s broader IT integration expertise means these connections can be designed with the data governance standards that pharma environments require. 4.3 Vendor validation, Audit trails, and 21 CFR Part 11 readiness 21 CFR Part 11 governs the use of electronic records and electronic signatures in FDA-regulated industries. Any low code platform used in a regulated context needs to support the relevant technical controls, including audit trails, access controls, and record integrity measures. Worth noting: platform capability is distinct from validated implementation. A platform designed to support 21 CFR Part 11 compliance still requires a validation protocol, installation qualification, and operational qualification before it can be used in a regulated process. TTMS can supports pharma clients through this validation process, drawing on experience with both Power Apps and Webcon BPS in governance-sensitive environments. This includes helping organizations build the documentation packages, test scripts, and change control procedures that regulators expect. 4.4 Leading platforms used in medtech enterprises and pharma in 2026 Platforms often considered for low-code, workflow automation, or regulated content workflows in pharma and medtech include low code environments include Microsoft Power Platform (encompassing Power Apps, Power Automate, and Power BI), Webcon BPS, Appian, ServiceNow, and Veeva Vault for specific regulatory content workflows. TTMS brings direct implementation experience with both Microsoft Power Apps and Webcon BPS in enterprise environments. The choice between them often comes down to the specific use case: Power Apps excels in broad departmental digitization and user-facing applications, while Webcon BPS is particularly strong for structured, compliance-heavy workflow automation. 5. Common barriers to low code AI adoption in pharma and how to overcome them Even when the business case is strong, adoption rarely happens without friction. The barriers in pharma are distinct from those in other industries, and they require specific strategies to address. 5.1 Regulatory uncertainty and validation concerns The most common hesitation in pharma IT is regulatory. Leaders worry that low code platforms will create compliance gaps, that regulators will scrutinize application builds differently, or that validation costs will negate the speed advantages. These concerns aren’t unfounded, but they’re often overstated. The key distinction is between the platform and the application built on it. A well-governed low code platform, implemented with proper validation protocols, is defensible in an audit. The answer to regulatory uncertainty isn’t to avoid low code; it’s to build robust validation frameworks around its use. TTMS helps pharma clients develop these frameworks as part of its implementation approach, ensuring that speed and compliance reinforce rather than trade off against each other. 5.2 Data quality and interoperability challenges Low code AI only delivers value when the data feeding it is reliable. Many pharma organizations discover their data quality and interoperability challenges are more significant than anticipated once they start digitizing workflows. Master data inconsistencies, siloed systems, and poorly documented data models can slow implementation considerably. Addressing this barrier means treating data governance as a prerequisite, not an afterthought. Before deploying low code AI tools in a new domain, organizations should map their data sources, identify quality issues, and define ownership. TTMS’s experience in IT system integration and business intelligence helps clients build this foundation as part of a broader digital transformation strategy. 5.3 Change management and workforce readiness Technology adoption ultimately depends on people. In pharma, where established processes carry regulatory weight, introducing new tools challenges deeply ingrained working habits. Resistance from quality teams, clinical operations staff, or manufacturing supervisors can stall a well-designed low code program. Effective change management requires more than a training session. It means engaging business stakeholders early in the design process, demonstrating tangible improvements to their day-to-day work, and building internal champions who advocate for the new approach. TTMS’s e-learning capabilities support this by enabling pharma organizations to develop structured training programs that scale adoption across large, distributed teams. 6. What to expect from low code AI in pharma through 2026 and beyond Market forecasts make the growth trajectory concrete. According to Technavio, the global low code AI platform market is projected to grow by USD 32.26 billion at a CAGR of 32.2% through 2029, driven by the democratization of AI, talent scarcity, and generative AI integration across sectors including healthcare. Grand View Research projects the broader low code application development platform market to reach USD 101.68 billion by 2030 at a CAGR of 22.5%, with AI-powered workflow optimization cited as a key growth driver in regulated industries. For pharma specifically, these figures signal a market where low code investment is no longer discretionary. By 2026, organizations that began their low code journeys in 2023 and 2024 will be moving beyond individual applications toward enterprise-wide platforms that govern how low code tools are built, deployed, and maintained. The citizen developer model will mature, with clearer governance frameworks defining what business teams can build independently versus what requires IT involvement. AI capabilities embedded in low code platforms will also deepen. Predictive analytics, natural language processing, and AI-assisted decision support will be available to business users through the same visual interfaces they use to build workflows today. This will raise new questions about model governance, explainability, and regulatory compliance for AI-generated recommendations in clinical and manufacturing contexts. Pharma organizations that build their low code governance structures now will be better positioned to incorporate these capabilities responsibly when the time comes. The relationship between IT and business functions will continue to shift as well. IT becomes a platform enabler rather than the sole application builder, business teams take greater ownership of their digital processes, and the boundary between technology and operations grows more fluid. That’s the direction the industry needs to move. 7. How TTMS can help your organization get the most from low code in pharma Implementing low code AI in a regulated industry isn’t simply a technology project. It’s an operational transformation that requires platform expertise, integration capability, regulatory awareness, and change management discipline. TTMS brings all of these to pharma clients as a single integrated partner. As a recognized Microsoft Power Apps development company, TTMS helps pharmaceutical organizations deploy Power Platform solutions that enable citizen developers while maintaining IT governance. This includes designing the platform architecture, configuring security and data policies, building initial application templates, and training business users to take ownership of their workflows. The result is faster delivery of digital solutions that remain auditable and maintainable. As an official Webcon Partner, TTMS also implements Webcon BPS for pharma clients who need structured, compliance-focused workflow automation. Webcon BPS’s process governance capabilities make it particularly well-suited for quality management, pharmacovigilance, and document control workflows where audit trail integrity and process standardization are non-negotiable. TTMS’s implementation approach incorporates the validation documentation and testing structures that pharma quality teams require. Beyond these two platforms, TTMS’s capabilities extend across the full scope of what a pharma low code program needs to succeed. Its AI implementation expertise enables integration of intelligent automation and predictive analytics into low code workflows. Its IT system integration experience ensures that new applications connect reliably to existing ERP, LIMS, and clinical data systems. Its managed services model means pharma clients can maintain and evolve their low code environments without building a dedicated internal platform team. Its e-learning capabilities allow organizations to develop scalable training programs that bring large, distributed pharma workforces up to speed on new digital tools, accelerating adoption and reducing resistance. If your organization is ready to explore how low code AI can solve real operational challenges, whether in manufacturing quality, clinical operations, supply chain, or pharmacovigilance, TTMS can help you build a practical roadmap and deliver results. Reach out to the TTMS team at ttms.com to start the conversation. FAQ What is low-code AI in the context of pharma? Low-code AI in pharma refers to the use of visual development platforms that incorporate artificial intelligence capabilities, enabling pharma professionals to build and automate applications without extensive programming knowledge. Examples include Microsoft Power Apps for rapid application development and Webcon BPS for structured process automation in regulated workflows. Is low-code AI compliant with pharmaceutical regulations like 21 CFR Part 11? Low-code platforms can be designed and implemented to support 21 CFR Part 11 requirements, including audit trails, electronic signatures, and access controls. Compliance depends on how the platform is configured and validated, though. Organizations must follow appropriate validation protocols regardless of the platform used. What types of Pharma processes benefit most from low-code AI? Quality deviation management, clinical trial data workflows, pharmacovigilance case intake, supply chain visibility, and batch release processes are among the highest-impact use cases. Essentially, any structured, repetitive process that currently relies on manual data entry or email-based approvals is a strong candidate. How long does it take to deploy a low-code AI solution in pharma? Deployment timelines vary by complexity and regulatory scope, but low code platforms routinely reduce development time from months to weeks for standard workflow applications. A validation-ready deviation management workflow, for example, can often be configured and tested within four to six weeks with the right implementation partner. What's the difference between low-code and no code for pharma? No code platforms are fully visual with no programming required, which limits customization. Low code platforms allow limited scripting alongside visual tools, giving developers more flexibility while still accelerating delivery. For regulated pharma environments, low code’s added flexibility usually makes it the more appropriate choice. How does TTMS support low code AI adoption in pharma? TTMS provides end-to-end low code implementation services, including platform selection, configuration, IT integration, validation support, and training. As both a Microsoft Power Platform partner and an official Webcon Partner, TTMS brings direct platform experience to pharma clients navigating complex digital transformation challenges.
Read